The founder and largest shareholder of the Russian pharmaceutical company Promomed, Pyotr Bely, has become the fifth Russian billionaire to amass a fortune in the pharmaceutical industry, according to Forbes. According to the newspaper, his fortune has exceeded $ 1 billion.
The basis of Bely’s fortune is the controlling stake in PAO Promomed (about 88%). As of June 9, the company’s shares on the Moscow Stock Exchange reached 420.85 rubles per share, valuing Bely’s shares at approximately 78.4 billion rubles.
Pyotr Bely was born in 1972. He graduated with honors from Moscow State University of Medicine and Dentistry in 2006. Bely founded the Promomed company in 2005. Its structure includes a research center and the Biokhimik plant in Saransk.
In 2024, Promomed conducted an IPO on the Moscow Stock Exchange at the upper limit of the price range of 375-400 rubles per share. The market estimated its value at 85 billion rubles. According to RNC Pharma, an analytical company, the company ranks second among the top 10 manufacturers of anti-obesity drugs.
Bely appeared on the Forbes list along with the co-owners of Ogment Investments, Viktor Kharitonin and Egor Kulkov (shares in Pharmstandart, Otis Pharma, Biocad, and Generium), Aleksey Repik, founder of R-Pharm, and Vikram Punia, president of Pharmasyntez.
Vadim Yakunin and Eduard Netylko, owners of Protek and Pulse, also amassed their fortunes thanks to the pharmaceutical industry.
